Triple-Drug cocktail aims to stall endometrial cancer
NCT ID NCT01797523
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times
Summary
This study tested whether a combination of three drugs—everolimus, letrozole, and metformin—can help control advanced or recurrent endometrial cancer. The 62 participants had cancer that came back or spread and had limited prior treatments. The goal was to see how many patients had their cancer shrink or stop growing, and to check safety.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Lyndon B Johnson General Hospital
Houston, Texas, 77026, United States
-
MD Anderson Cooper Cancer Center
Voorhees Township, New Jersey, 08043, United States
-
Memorial City Medical Center
Houston, Texas, 77024, United States
-
Sacred Heart Health Systems
Pensacola, Florida, 32504, United States
-
The Woman's Hospital of Texas
Houston, Texas, 77054, United States
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- What raises endometrial cancer risk in black women? a study digs in
- Can immunotherapy plus hormones spare the womb in early endometrial cancer?
- Can a new drug tackle Hard-to-Treat gynecologic cancers?
- Can a pill restore the Body's tumor suppressor to fight multiple cancers?
- Could gentle yoga and breathing ease Cancer's lingering toll?